Global Pernicious Anemia Market Report 2022-2028: Increasing Prevalence of Autoimmune Conditions Driving Sector Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Pernicious Anemia Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The global pernicious anemia diagnosis and treatment market is anticipated to grow at a significant CAGR of 7.1% during the forecast period. Pernicious anemia is a disease in which the formation of red blood cells becomes slow due to deficiency of vitamin B-12 in the human body. The prime cause behind the disease is an autoimmune disorder in which the antibody released by the immune system harms the intrinsic factor present in the stomach.

The intrinsic factors play a vital role in the absorption of vitamin B-12 from the food. The deficiency of B-12 leads to a shortage of red blood cells in the bloodstream thereby leading to carry less oxygen to the blood. Elderly people are more prone to such diseases. The increasing prevalence of autoimmune conditions or intestinal diseases is the major motivating factor for the growth of the global pernicious anemia market. Moreover, effective medication techniques for treating autoimmune disorders also account for the growth of the market.

The lack of awareness about the treatment of disease and the high cost of the drug is the major factors restraining the growth of the market. The supportive government regulations and increased expenditure for the development of healthcare infrastructure will create more room for future growth of the market. Moreover, the rapid research and development in the field of novel treatment methods will also help in increasing the market across the globe.

Market Players Outlook

The competition in the global pernicious anemia diagnosis and treatment market is moderate as the companies present in the market are not so active. The market players are engaged in providing various B-12 vitamin injections, sprays, immunosuppressant drugs, and tests for Intrinsic factor deficiency. The key players in the pernicious anemia market include American Regent, Inc., Daiichi Sankyo Co, Ltd., Emisphere Technologies, Inc, and so on. The companies are engaged in rapid research and development for the development of effective treatment measures for the disease.

The Report Covers

• Market value data analysis of 2020 and forecast to 2027.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global pernicious anemia diagnosis and treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

3. Competitive Landscape

4. Market Determinants

5. Market Segmentation

6. Regional Analysis

7. Company Profiles

Companies Mentioned

• American Regent, Inc.
• Bio-Rad Laboratories, Inc.
• BioVision, Inc.
• Cleveland HeartLab, Inc.
• Daiichi Sankyo Co., Ltd.
• DSM Nutritional Products AG
• Emisphere Technologies, Inc.
• Endo Pharmaceuticals Plc.
• GlaxoSmithKline Plc.
• Guardian Healthcare Services Pvt. Ltd.
• Laboratory Corporation of America Holdings
• Monobind, Inc.
• Pfizer, Inc.
• Pharmacosmos A/S
• Pharmavite, LLC
• Premier Research Labs
• Swanson Health Products
• The Synergy Company
• Trinity Biotech Plc.

For more information about this report visit https://www.researchandmarkets.com/r/qe048j